Hepatocellular Carcinoma by BCLC Stage
7
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
Brazilian Reality of Hepatocellular Carcinoma
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer